Top Markets
Coin of the day
ZyVersa Therapeutics, Inc. ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc.

ZVSA
Rank in Stocks #38793
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical... ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
Share Price
$0.099
Market Cap
$801.50K
Change (1 day)
0.00%
Change (1 year)
-34.44%
Country
US
Trade ZyVersa Therapeutics, Inc. (ZVSA)

Category

Earnings for ZyVersa Therapeutics, Inc. (ZVSA)
Earnings in 2026 TTM: 0
According to ZyVersa Therapeutics, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for ZyVersa Therapeutics, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE